Literature DB >> 10369460

Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment.

Y Y Tan1, J D Wade, G W Tregear, R J Summers.   

Abstract

The binding characteristics of the relaxin receptor in rat atria, uterus and cortex were studied using a [33P]-labelled human gene 2 relaxin (B33) and quantitative receptor autoradiography. The binding kinetics of [33P]-human gene 2 relaxin (B33) were investigated in slide-mounted rat atrial sections. The binding achieved equilibrium after 60 min incubation at room temperature (23+/-1 degrees C) and dissociated slowly. The association and dissociation rate constants were 4.31+/-0.34x10(8) M(-1) x min(-1) and 1.55+/-0.38x10(-3) min(-1) respectively. Thus, the kinetic dissociation constant was 3.46+/-0.59 pM. Binding was saturable to a single population of non-interacting sites throughout atria, in uterine myometrium and the 5th layer of cerebral cortex. The binding affinities (pK(D)) of [33P]-human gene 2 relaxin (B33) were 8.92+/-0.09 in atrial myocardium and 8.79+/-0.04 in cerebral cortex of male rats, and 8.79+/-0.10 in uterine myometrium. Receptor densities in the cerebral cortex and atria were higher than in uterine myometrium, indicating that relaxin also has important roles in non-reproductive tissues. In male rats, treatment with 17beta-oestradiol (20 microg in 0.1 ml sesame oil s.c., 18-24 h) significantly decreased the density of relaxin receptors in atria and cerebral cortex. Identical treatment in female rats had no significant effect in atria and cerebral cortex, but it significantly increased the density of relaxin receptors in uterine myometrium. Relaxin binding was competitively displaced by porcine and rat native relaxins. Porcine native relaxin binds to the relaxin receptor in male rat atria (8.90+/-0.02), and cerebral cortex (8.90+/-0.03) and uterine myometrium (8.89+/-0.03) with affinities not significantly different from human gene 2 (B33) relaxin. Nevertheless, rat relaxin binds to the receptors with affinities (8.35+/-0.09 in atria, 8.22+/-0.07 in cerebral cortex and 8.48+/-0.06 in uterine myometrium) significantly less than human gene 2 (B33) and porcine relaxins. Quantitative receptor autoradiography is the method of choice for measurement of affinities and densities of relaxin receptor in atria, uterine myometrium and cerebral cortex. High densities were found in all these tissues. 17beta-oestradiol treatment produced complex effects where it increased the densities of relaxin receptors in uterus but decreased those in atria and cerebral cortex of the male rats, and had no effect on the atria and cerebral cortex of the female rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369460      PMCID: PMC1565996          DOI: 10.1038/sj.bjp.0702517

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Mechanism of the haemotensive action of porcine relaxin in anaesthetized rats.

Authors:  L J Parry; R S Poterski; A J Summerlee; S A Jones
Journal:  J Neuroendocrinol       Date:  1990-02-01       Impact factor: 3.627

2.  Lesion of the subfornical organ affects the haemotensive response to centrally administered relaxin in anaesthetized rats.

Authors:  A D Mumford; L J Parry; A J Summerlee
Journal:  J Endocrinol       Date:  1989-09       Impact factor: 4.286

3.  Purification and characterization of rat relaxin.

Authors:  O D Sherwood
Journal:  Endocrinology       Date:  1979-04       Impact factor: 4.736

Review 4.  Relaxin: more than just a hormone of pregnancy.

Authors:  H Kakouris; L W Eddie; R J Summers
Journal:  Trends Pharmacol Sci       Date:  1993-01       Impact factor: 14.819

Review 5.  Why are long-acting beta-adrenoceptor agonists long-acting?

Authors:  G P Anderson; A Lindén; K F Rabe
Journal:  Eur Respir J       Date:  1994-03       Impact factor: 16.671

6.  Target tissues for relaxin in the rat: tissue distribution of injected 125I-labeled relaxin and tissue changes in adenosine 3',5'-monophosphate levels after in vitro relaxin incubation.

Authors:  S H Cheah; O D Sherwood
Journal:  Endocrinology       Date:  1980-04       Impact factor: 4.736

7.  A new method for receptor autoradiography: [3H]opioid receptors in rat brain.

Authors:  W S Young; M J Kuhar
Journal:  Brain Res       Date:  1979-12-28       Impact factor: 3.252

8.  The chemical synthesis of rat relaxin and the unexpectedly high potency of the synthetic hormone in the mouse.

Authors:  E E Büllesbach; C Schwabe
Journal:  Eur J Biochem       Date:  1996-10-15

9.  Relaxin increases the firing rate of supraoptic neurones and increases oxytocin secretion in the rat.

Authors:  S A Way; G Leng
Journal:  J Endocrinol       Date:  1992-01       Impact factor: 4.286

10.  Relaxin binding in the rat heart atrium.

Authors:  P L Osheroff; M J Cronin; J A Lofgren
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

View more
  10 in total

Review 1.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 2.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

3.  Role of protein kinase C β₂ in relaxin-mediated inhibition of cardiac fibrosis.

Authors:  W Su; P Wang; H Chen; H Li
Journal:  J Endocrinol Invest       Date:  2014-04-11       Impact factor: 4.256

Review 4.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

5.  Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Authors:  Andrew R Kompa; Chrishan S Samuel; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

Review 6.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Regulation of receptor signaling by relaxin A chain motifs: derivation of pan-specific and LGR7-specific human relaxin analogs.

Authors:  Jae-Il Park; Jenia Semyonov; Wei Yi; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

8.  Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies.

Authors:  Jiangning Tan; John R Tedrow; Justin A Dutta; Brenda Juan-Guardela; Mehdi Nouraie; Yanxia Chu; Humberto Trejo Bittar; Kritika Ramani; Partha S Biswas; Kristen L Veraldi; Naftali Kaminski; Yingze Zhang; Daniel J Kass
Journal:  Am J Respir Crit Care Med       Date:  2016-12-01       Impact factor: 21.405

9.  Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients.

Authors:  Jasinda H Lee; Shu Qing Koh; Simone Guadagna; Paul T Francis; Margaret M Esiri; Christopher P Chen; Peter T-H Wong; Gavin S Dawe; Mitchell K P Lai
Journal:  Psychopharmacology (Berl)       Date:  2015-11-06       Impact factor: 4.530

10.  Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway.

Authors:  Xiao Wei; Yuan Yang; Yin-Jiu Jiang; Jian-Ming Lei; Jing-Wen Guo; Hua Xiao
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.